.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Insurers, States Strike Hepatitis C Deals

February 1, 2015

Insurers and state Medicaid agencies have been eager to strike a deal with pharmaceutical companies to secure discounts on pricey hepatitis C drugs.

Both insurers and state Medicaid agencies are working to secure discounts on pricey hepatitis C drugs.

Insurers and states alike have been eager to strike a deal with the pharmaceutical companies, especially considering

the backlash Gilead's Sovaldi received last year after the company placed a $100,000 per person price tag on the drug. Harvoni is Gilead's follow-up to Sovaldi.

Missouri signed a deal with AbbVie this week to make Viekira Park the preferred drug covered by the state's Medicaid program, noted the Wall Street Journal

. The drug will replace Sovaldi. AbbVie will "provide a rebate to states participating in the consortium."